Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Prof. Petr Widimsky ,
Primary PCI in the treatment of acute ST elevation myocardial infarction: focus on adjunctive pharmacologic treatment.
Primary percutaneous coronary intervention (p-PCI) has become the dominant reperfusion treatment for ST-elevation acute myocardial infarction (STEMI).
The optimal logistics are to get the patient with sudden chest pain lasting > 15 minutes quickly to the cath-lab. An immediate call to central emergency is to be placed, which sends an ambulance equipped with 12-leads ECG. Typical ECG changes (ST elevations, ST depressions, bundle branch block) should trigger an immediate transfer to the cath-lab table. During the transfer, optimal treatment includes aspirin, clopidogrel and unfractioned heparin. In the cath lab, coronary nitrates are to be given, clopidogrel then for a month thereafter and aspirin for life.
During the last three years (2003-5) primary percutaneous coronary intervention (p-PCI) has become the dominant reperfusion treatment for ST-elevation acute myocardial infarction (STEMI) in most European countries. With this change in the organisation of acute coronary care many practical questions arise.
The aim of this contribution is to provide practical recommendations based on current ESC guidelines for PCI (1) and on the large experience of the Czech Republic, where almost all (93%) STEMI presenting within 12 hours after symptom onset are treated by p-PCI and the use of thrombolysis in this setting is very rare (7%). Transfer for primary PCI and the choice of reperfusion therapy in relation to symptoms duration was described by Kristensen et al. (2, 3).
The optimal logistics means that a 12-leads electrocardiogram (ECG) is recorded during the first medical contact and the patient is transferred immediately after diagnostic ECG directly to cath-lab table.
Aspirin should be given to all patients with STEMI (if no contraindication is present) as soon as possible after the diagnosis is established. The preferred route is intravenous (lysin salicylate 0,5 g) or oral (200 - 400 mg) with chewing the drug. Clopidogrel is increasingly used, preferably with a loading dose of 600 mg. Despite lacking large evidence from randomised trials, the indirect data clearly benefit this approach. Due to the fact that ca 90% of patients arriving at the cath-lab with suspected STEMI finally undergo PCI and 90% of these receive a stent, clopidogrel would be given anyhow. Our own approach currently is that when a STEMI patient did not receive prehospital clopidogrel, we give him (her) 600 mg immediately upon arrival at the cath-lab. Unfractionated heparin is still the "golden standard" therapy in patients with STEMI undergoing primary PCI. Most ambulances in the Czech Republic give the iv. bolus of 5000 or 10000 units in the prehospital phase before / during transfer to PCI center. Thrombolytics are not indicated in this setting. The concept of "lytics-facilitated PCI" has been proved to be inferior compared to simple primary PCI strategy by several randomised trials (LIMI, PRAGUE, ASSENT-4 PCI). The explanation is complex: more strokes and more reinfarctions (stent thrombosis) after "facilitated PCI", rather short "ECG - PCI" time delays in primary PCI patients (short delay makes additional benefit from lytics unlikely), etc.
Intracoronary nitrates are injected to unmask vasospasm and to estimate true vessel sizes (for more appropriate selection of a stent). GP IIb/IIIa inhibitors for PCI in STEMI are less well investigated compared with acute coronary syndromes without ST elevation. This holds true especially for tirofiban and eptifibatide. Abciximab has been evaluated in five randomised, controlled trials (RAPPORT, ISAR-2, CADILLAC, ADMIRAL and ACE) in association with primary PCI.
A recent meta-analysis concluded that abciximab, as adjunctive therapy to PCI, reduces mortality, TVR, and MACE at 6 months after STEMI. The long-term benefits of abciximab administered during coronary artery stenting in patients with STEMI require more investigation. However, it is not known whether these benefits are still true with the current clopidogrel pre-treatment. All the mentioned trial tested abciximab in the setting without clopidogrel pre-treatment. No-reflow / slow-flow fenomenon are sometimes treated by intracoronary verapamil, adenosin, nitroprusside or even diluted (1:100 000) epinephrine. None of these drugs was clearly shown to improve the outcome. Low molecular weight heparins have no evidence to support their use over UFH for PCI in STEMI. There is currently no evidence-based recommendation to use direct thrombin inhibitors for PCI in STEMI. We specifically warn against the "bailout" use of thrombolytics in the cath-lab in efforts to recanalise the infarct arteries when primary PCI fails. The success rate of primary PCI in achieving TIMI 2-3 flow in the infarct vessel is 90-95%. In those few patients in whom primary PCI fails to open the vessel, there is a very small likelihood that thrombolytics will be successfull. The opposite is true: the unsucessfull PCI is frequently associated with vessel dissection or even guide wire penetration outside the vessel. This usually has no clinical consequences unless lytics are used. When lytics are given to a patient with failed primary PCI, cardiac tamponade may be the final result of this effort...
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Guidelines for Percutaneous Coronary Interventions The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology S. Silber, P. Albertsson, F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jørgensen, J. Marco, J. E. Nordrehaug, W. Ruzyllo, P. Urban, G. W. Stone, W. Wijns. European Heart Journal (2005) 26, 804–847 http://eurheartj.oxfordjournals.org/cgi/reprint/
2. S.D. Kristensen, H.R. Andersen: Acute ST-elevation myocardial infarction – is transferral for primary PCI an option ? E-Journal of Cardiology Practice, vol. 2, no. 10. /knowledge/cardiology_practice/ejournal_vol2/Vol2_no10.htm
3. S.D. Kristensen, K. Huber, R. De Caterina: ST-elevation myocardial infarction – should choice of reperfusion therapy depend on the duration of symptoms ? E-Journal of Cardiology Practice, vol. 3, no. 14. /knowledge/cardiology_practice/ejournal_vol3/vol3n14.htm
4. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.Lancet 2003;361:13-20 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12517460&query_hl=2&itool=pubmed_docsum
Prof. P. Widimsky Prague, Czech Republic Nucleus Member of the Working Group on Interventional Cardiology
Our Mission: To Reduce the Burden of Cardiovascular Disease
© 2019 European Society of Cardiology. All rights reserved